Centre de Génétique Humaine, Université de Franche-Comté, CHU, Besançon, France.
Unité de recherche en neurosciences intégratives et cognitives EA481, Université de Franche-Comté, Besançon, France.
Mov Disord. 2020 Jul;35(7):1224-1232. doi: 10.1002/mds.28058. Epub 2020 May 5.
Hemizygous mutations in GRIA3 encoding the GluA3 subunit of the amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor are known to be associated with neurodevelopmental disorders, including intellectual disability, hypotonia, an autism spectrum disorder, sleep disturbances, and epilepsy in males.
To describe a new and consistent phenotype in 4 affected male patients associated with an undescribed deleterious variant in GRIA3.
We evaluated a large French family in which segregate a singular phenotype according to an apparent X-linked mode of inheritance. Molecular analyses using next generation sequencing and in vitro functional studies using 2-electrode voltage clamp recordings on Xenopus laevis oocytes and a β-lactamase reporter assay in transfected human embryonic kidney (HEK293) cells were performed.
In addition to mild intellectual disability and dysarthria, affected patients presented a tightly consistent early-onset movement disorder combining an exaggerated startle reflex with generalized chorea and multifocal myoclonus. The unreported GRIA3 missense variant c.2477G > A; p.(Gly826Asp) affecting the fourth transmembrane domain of the protein was identified in index patients and their unaffected mothers. Functional studies revealed that variant receptors show decreased current response evoked by agonist (ie, kainic acid and glutamate) and reduced expression on the cell surface in favor of pathogenicity by a loss-of-function mechanism.
Taken together, our results suggest that apart from known GRIA3-related disorders, an undescribed mutation-specific singular movement disorder does exist. We thus advocate considering GRIA3 mutations in the differential diagnosis of hyperekplexia and generalized chorea with myoclonus. © 2020 International Parkinson and Movement Disorder Society.
编码氨基-3-羟基-5-甲基-4-异恶唑丙酸受体 GluA3 亚基的 GRIA3 中的杂合突变与神经发育障碍有关,包括男性的智力残疾、张力减退、自闭症谱系障碍、睡眠障碍和癫痫。
描述与 GRIA3 中未描述的有害变异相关的 4 名受影响男性患者的新的一致表型。
我们评估了一个大型法国家族,该家族根据明显的 X 连锁遗传模式分离出一种奇异的表型。使用下一代测序进行分子分析,以及使用 Xenopus laevis 卵母细胞的双电极电压钳记录和转染的人胚肾 (HEK293) 细胞中的β-内酰胺酶报告基因测定进行体外功能研究。
除了轻度智力残疾和构音障碍外,受影响的患者还表现出一种紧密一致的早发性运动障碍,包括夸张的惊跳反射与全身舞蹈症和多灶性肌阵挛相结合。在索引患者及其未受影响的母亲中发现了未报道的 GRIA3 错义变异 c.2477G > A;p.(Gly826Asp),该变异影响蛋白的第四跨膜域。功能研究表明,变体受体对激动剂(即海人酸和谷氨酸)引起的电流反应降低,并且在细胞表面的表达减少,有利于通过功能丧失机制产生致病性。
总之,我们的研究结果表明,除了已知的 GRIA3 相关疾病外,还存在一种未描述的突变特异性单一运动障碍。因此,我们主张在鉴别诊断高张力性反射亢进和全身性舞蹈症伴肌阵挛时考虑 GRIA3 突变。